


1. (Currently Amended) A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, for inhibition of kinase activity wherein the kinase activity is CDK2 activity, PDK1 activity, CHK1 activity, or combinations thereof:



wherein

Ring A is an optionally substituted phenyl~~carbocyclic or heterocyclic~~ radical,

Alk represents an optionally substituted divalent C_1 - C_6 alkylene radical;

n is 0 ~~or 1~~;

Q represents a radical of formula $-(Alk^1)_p-(X)_r-(Alk^2)_s-Z$ wherein ~~in any compatible combination~~

Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring,

Alk^1 and Alk^2 are optionally substituted divalent C_1 - C_6 alkylene radicals which may contain a $-O-$, $-S-$ or $-NR^A$ -link, wherein R^A is hydrogen or C_1 - C_6 alkyl,

X represents $-O-$, $-S-$, $-(C=O)-$, $-(C=S)-$, $-SO_2-$, $-SO-$, $-C(=O)O-$, $-OC(=O)-$, $-C(=O)NR^A-$, $-NR^AC(=O)-$, $-C(=S)NR^A-$, $-NR^AC(=S)-$, $-SO_2NR^A-$, $-NR^ASO_2-$, $-OC(=O)NR^A-$, -

NRAC(=O)O-, or -NR^A- wherein R^A is hydrogen or C₁-C₆ alkyl, and

p, r and s are independently 0 or 1,

R₁ represents a radical -(Alk³)_a-(Y)_b-(Alk⁴)_d-B wherein a, b and d are independently 0 or 1,

Alk³ and Alk⁴ are optionally substituted divalent C₁-C₃ alkylene radicals,

Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -O-, -S-, or -NR^A- wherein R^A is hydrogen or C₁-C₆ alkyl,

B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -NR^A- and b is 1, then R^A and the radical-(Alk⁴)_d-B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring,

R represents hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms.

Claims 2-4 (Canceled)

5. (Previously Presented) The compound as claimed in claim 1 wherein ring A is unsubstituted or substituted by methyl, ethyl, methylenedioxy, ethylenedioxy, methoxy, ethoxy, methylthio, ethylthio, hydroxy, hydroxymethyl, hydroxyethyl, mercapto, mercaptomethyl, mercaptoethyl, amino, mono- or di-methylamino, mono- or di-ethylamino, fluoro, chloro, bromo, cyano, N-morpholino, N-piperidinyl, or N-piperazinyl, the latter being optionally C₁-C₆ alkyl- or benzyl-substituted on the free ring nitrogen, dimethylaminosulfonyl, phenylsulfonyl or phenoxy.

6. (Withdrawn) The compound as claimed in claim 1 wherein Q is hydrogen and the ring A is 4-(dimethylaminosulfonyl)-phenyl, 4-(phenylsulfonyl)-phenyl, 4-(phenoxy)-phenyl, 3-chloro-4-(dimethylaminosulfonyl)-phenyl, 3-chloro-4(phenylsulfonyl)-phenyl, 3-chloro-4-(phenoxy)-phenyl, 3-methoxy-4(dimethylaminosulfonyl)-phenyl, 3-methoxy-4-(phenylsulfonyl)-phenyl, or 3-methoxy-4-(phenoxy)-phenyl.

Claims 7-9 (Canceled)

10. (Withdrawn) The compound as claimed in claim 1 wherein each of p, r and s is 0, and Z is hydrogen.

11. (Withdrawn) The compound as claimed in claim 1 wherein p, r and s are each 0, and Z is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

12. (Withdrawn) The compound as claimed in claim 11 wherein Z is an optionally substituted phenyl, cyclopentyl, cyclohexyl, pyridyl, morpholino, piperidinyl, or piperazyl ring.

13. (Previously Presented) The compound as claimed in claim 1 wherein one or more of p, r and s is 1, and Z is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring.

14. (Withdrawn) The compound as claimed in claim 13 wherein p, s, or both are each 1 and r is 0

15. (Withdrawn) The compound as claimed in claim 13 wherein each of p, r, and s is 1.

16. (Previously Presented) The compound as claimed in claim 13 wherein p and s are each 0 and r is 1.

17. (Previously Presented) The compound as claimed in claim 16 wherein X is -SO₂-, -O-, a sulfonamide radical -NR^ASO₂- or a carboxamide radical -NR^AC(=O)- with the N atom linked to the ring A.
18. (Withdrawn) The compound as claimed in claim 13 wherein p is 0, r is 1, s is 1 or 0, and X is a sulfonamide radical -NR^ASO₂- or a carboxamide radical -NR^AC(=O)- with the N atom linked to the ring A.
19. (Withdrawn) The compound as claimed in claim 17 wherein R^A is hydrogen or methyl.
20. (Withdrawn) The compound as claimed in claim 18 wherein s is 1 and Z is hydrogen.
21. (Previously Presented) The compound as claimed in claim 18 or wherein s is 0 and Z is an optionally substituted mono cyclic carbocyclic or heterocyclic ring.
22. (Previously Presented) The compound as claimed in claim 21 wherein Z is optionally substituted phenyl.
23. (Withdrawn) The compound as claimed in claim 1 wherein in the radical R₁ a, b and d are all 0.
24. (Previously Presented) The compound as claimed in claim 1 wherein in the radical R₁ a and d are each 0 and b is 1.
25. (Withdrawn) The compound as claimed in claim 1 wherein in the radical R₁ b is 0 and at least one of a and d is 1.
26. (Withdrawn) The compound as claimed in claim 23 wherein in the radical R₁, B is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

27. (Withdrawn) The compound as claimed in claim 26 wherein B is an optionally substituted cyclopentyl, cyclohexyl, phenyl, 2-,3-, or 4-pyridyl, 2-, or 3-thienyl, 2-, or 3-furanyl, pyrrolyl, pyranlyl, or piperidinyl ring.

28. (Withdrawn) The compound as claimed in claim 27 wherein optional substituents are selected from methyl, ethyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, methylthio, ethylthio, hydroxy, hydroxymethyl, hydroxyethyl, mercapto, mercaptomethyl, mercaptoethyl, amino, mono- and di-methylamino, monoand di-ethylamino, fluoro, chloro, bromo, cyano, N-morpholino, N-piperidinyl, N-piperazinyl.

29. (Previously Presented) The compound as claimed in claim 1 wherein R₁ is optionally substituted cyclohexyloxy; cyclohexylamino; cyclohexylmethyl, or piperidin-1-ylmethyl.

30. (Previously Presented) The compound as claimed in claim 1 wherein R₁ is 4aminocyclohexyloxy; 4-aminocyclohexylamino; 4-hydroxycyclohexylamino, 4aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl.

31. (Previously Presented) The compound as claimed in claim 1 wherein R is hydrogen, chloro, bromo methyl, ethyl, n-propyl, iso-propyl, n-, sec- or tert-butyl, methoxy, methylthio, ethoxy, ethylthio, or a phenyl, benzyl, cyclopropyl, cyclopentyl, cyclohexyl, 2-, 3-, or 4- pyridyl, phenyl, pyridyl, morpholino, piperidinyl, or piperazyl ring.

32. (Previously Presented) The compound as claimed in claim 1 wherein R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

33. (Currently Amended) The compound as claimed in claim 1 wherein in the compound of formula (I) ~~n is 0, ring A is optionally substituted phenyl,~~ Q is dimethylaminosulfonyl, phenylsulfonyl or phenoxy; R¹ is 4-aminocyclohexyloxy, 4aminocyclohexylamino, 4-

hydroxycyclohexylamino, 4-aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl, and R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

34. (Withdrawn - Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate kinase activity in mammals comprising administering to the mammal an amount of a compound of formula (I) as defined in claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said kinase activity wherein the kinase activity is CDK2 activity, PDK1 activity, CHK1 activity, or combinations thereof.


35. (Canceled)

36. (Canceled)

37. (Withdrawn) The method of treatment as claimed in claim 34, wherein the kinase activity is associated with cancer, psoriasis or restenosis.

38. (Withdrawn) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a salt, N-oxide, hydrate or solvate thereof, together with a pharmaceutically acceptable carrier.

39. (Withdrawn) A compound of formula (I), or a salt, N-oxide, hydrate or solvate thereof,



wherein n is 0, ring A is optionally substituted phenyl, Q is dimethylaminosulfonyl, phenylsulfonyl or phenoxy, R¹ is 4aminocyclohexyloxy; 4-aminocyclohexylamino; 4-hydroxycyclohexylamino; 4aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl, and R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

40 (Withdrawn) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 39 together with a pharmaceutically acceptable carrier.